Black Diamond Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Black Diamond Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, equals 92% of its market value (net cash). Higher than 87% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 3/3Sales grew in 1 of the last 3 years; profit grew in 3 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
8.0×Debt due within a year is covered 8.0 times by its yearly operating cash.
Higher than 83% of Healthcare companies in United States.
Cash Cushion Ratio
+92%Cash, after subtracting all debt, equals 92% of its market value (net cash).
Higher than 87% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Black Diamond Therapeutics, Inc. made a loss over the last year. Black Diamond Therapeutics, Inc. owes $0.23 for every $1 it owns. Black Diamond Therapeutics, Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossBlack Diamond Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.12The share price is 1.12 times Black Diamond Therapeutics, Inc.'s book value per share, lower than 76% of Healthcare companies in United States.
Market cap
$108 MThe total market value of all of Black Diamond Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 64% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$96 MWhat Black Diamond Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.68Net worth divided by the number of shares. The share price of $1.88 is 1.1 times this, which is the P/B above.
Return on equity (ROE)
-37.2%Black Diamond Therapeutics, Inc. lost 37.2% of its shareholders' money over the last year, higher than 57% of Healthcare companies in United States.
Owes vs Owns
0.23×Black Diamond Therapeutics, Inc. owes $0.23 for every $1 it owns (low), lower than 68% of Healthcare companies in United States.
Dividend yield
NoneBlack Diamond Therapeutics, Inc. does not currently pay a dividend.
Profit growth
Back to profitBlack Diamond Therapeutics, Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Profit margin
32.0%Black Diamond Therapeutics, Inc. keeps $32 of every $100 of revenue as net profit.
Cash quality
1.3×Cash from Black Diamond Therapeutics, Inc.'s business was 1.3× its reported profit in the year to Dec 2025 — its profit turned into cash.
Cash vs debt
Net cashBlack Diamond Therapeutics, Inc. held $110 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Black Diamond Therapeutics, Inc.: $108 M ÷ $96 M (30 Jun 2026) = 1.1.
What is Black Diamond Therapeutics, Inc.'s return on equity?
Black Diamond Therapeutics, Inc. lost 37.2% of its shareholders' money over the last year, higher than 57% of Healthcare companies in United States.
How much does Black Diamond Therapeutics, Inc. owe compared with what it owns?
Black Diamond Therapeutics, Inc. owes $0.23 for every $1 it owns (low), lower than 68% of Healthcare companies in United States.
Does Black Diamond Therapeutics, Inc. pay a dividend?
No. Black Diamond Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.